ArticleBMC cardiovascular disorders2025
The correlation between serum ECM1 and cardiac fibrosis in heart failure patients.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic heart failure (HF) is characterized by progressive myocardial injury and remodeling. Extracellular matrix protein 1 (ECM1) and low-density lipoprotein receptor-related protein 1 (LRP1) have been implicated in fibrosis; however, their clinical significance in HF remains unclear. This study aimed to investigate the relationship between circulating ECM1 and LRP1 levels and cardiac dysfunction and fibrosis markers in patients with chronic HF.
methodsWe conducted a cross-sectional study of 93 patients with chronic HF (LVEF ≤ 50%) and 80 age- and sex-matched controls with stable cardiovascular disease (LVEF > 50%). Clinical data, routine biochemical parameters, and echocardiography images were obtained. Serum ECM1, LRP1, TGF-β1, CTGF, and PICP levels were measured using ELISA. Statistical analyses included group comparisons, receiver operating characteristic (ROC) curve analysis, and Spearman's correlation with Bonferroni adjustment for multiple testing.
resultsPatients with HF had significantly higher serum ECM1 (157.3 ± 28.4 vs. 92.8 ± 14.7 pg/mL) and LRP1 (14.3 ± 2.6 vs. 8.7 ± 1.3 µg/mL) levels than controls (both P < 0.001). ROC analysis showed that ECM1 discriminated HF from non-HF patients with an AUC of 0.985, sensitivity of 91.4%, and specificity of 98.7%. Both ECM1 and LRP1 levels increased with worsening NYHA class. ECM1 was negatively correlated with LVEF and positively correlated with CK-MB, NT-proBNP, TGF-β1, CTGF, PICP, and LRP1. LRP1 expression was also correlated with LVEF, CK-MB, NT-proBNP, and fibrosis marker levels.
conclusionsCirculating ECM1 and LRP1 levels are elevated in chronic HF and are closely associated with cardiac dysfunction and fibrosis. These findings suggest that ECM1 and LRP1 could serve as novel biomarkers for myocardial remodeling, with potential utility in the risk stratification and monitoring of patients with HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.